Similar studies for GEO DataSets (Select 200050948) - GEO DataSets

Select item 2000509481.

Expression Data from transNOAH breast cancer trial

(Submitter supplied) These data can be used for evaluation of the clinical utility of the research-based PAM50 subtype predictor in predicting pathological complete response (pCR) and event-free survival (EFS) in women enrolled in the NeOAdjuvant Herceptin (NOAH) trial. The NeOAdjuvant Herceptin [NOAH] trial demonstrated that trastuzumab significantly improves pCR rates and 3-year event-free survival (EFS) in combination with neoadjuvant chemotherapy compared with neoadjuvant chemotherapy alone in patients with HER2+ breast cancer.

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS5027
Platform:: GPL570
156 Samples

Download data: CEL

Series

Accession:: GSE50948

ID:: 200050948

Select item 50272.

NeOAdjuvant Herceptin (NOAH) trial: formalin-fixed, paraffin-embedded breast cancer biopsies

Analysis of FFPE core biopsies from pre-treated patients with HER2+ breast cancer (BC) randomized to receive neoadjuvant chemotherapy only or chemotherapy+trastuzumab (herceptin). Results provide insight into the molecular basis of survival outcomes following trastuzumab-based chemotherapy.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 2 genotype/variation, 2 other, 2 protocol sets

Platform:: GPL570
Series:: GSE50948
156 Samples

Download data: CEL

DataSet

Accession:: GDS5027

ID:: 5027

Select item 2000663993.

Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with chemotherapy plus trastuzumab and lapatinib as neoadjuvant therapy for HER2-positive breast cancer

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:: Homo sapiens

Type:: Expression profiling by array; Genome variation profiling by SNP array

Platforms:: GPL6801 GPL570
156 Samples

Download data: CEL, CNCHP

Series

Accession:: GSE66399

ID:: 200066399

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2002345194.

NSABP B-41: A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

(Submitter supplied) We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients.

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platform:: GPL24676
245 Samples

Download data: TXT

Series

Accession:: GSE234519

ID:: 200234519

PubMed Full text in PMC Similar studies

Select item 2000223585.

Clinical and Pathologic Response of the Primary Tumor in Women Receiving Neoadjuvant Docetaxel-Capecitabine (+/- Trastuzumab) Chemotherapy

(Submitter supplied) Results: In subjects who completed treatment and surgery, the pCR and near-complete response rates were 15.8% in HER2-negative and 50% in HER2-positive subjects. When stratified by genomic subtype, subjects of the HER2-enriched subtype had the best response (66.7%), the luminal A (11%) and B (4.8%) subtypes the poorest. Of 147 patients tested for p53 mutations using the AmpliChip test, 78 variants were detected; 55 were missense. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL5325
158 Samples

Download data

Series

Accession:: GSE22358

ID:: 200022358

Select item 2000763606.

03-311 Trastzumab preoperative Trial of Early Stage HER2+ BRCA

(Submitter supplied) Tumor core biopsies were obtained at baseline and after brief-exposure to single-agent trastuzumab from patients enrolled on the 03-311 trial. Gene expression profiling was conducted on these tumor biopsies to identify signatures of response to preoperative therapy. This study was initiated to identify biomarkers of response to preoperative trastuzumab-conotaining therapy. We performed transcriptional profiling of patient tumor biopsies obtained at baseline and post brief-exposure to trastuzumab to test the hypothesis that transcriptional changes upon brief-exposure to therapy can provide an early readout of subsequent response.

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL6947
100 Samples

Download data: IDAT, TXT

Series

Accession:: GSE76360

ID:: 200076360

PubMed Full text in PMC Similar studies Analyze with GEO2R

Select item 2001163357.

CALGB 40601: Randomized Phase III Trial of Paclitaxel Combined With Trastuzumab, Lapatinib, or Both As Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer

(Submitter supplied) CALGB 40601 was activated as a 3-arm study (paclitaxel + trastuzumab + lapatinib [THL], paclitaxel + trastuzumab [TH] and paclitaxel + lapatinib [TL]). In December 2010, twoneoadjuvant studies were presented at the Cancer Therapy and Research Center-American Association for Cancer Research (CTRC-AACR) San Antonio Breast Cancer Symposium that affected the scientific and practical enthusiasm for the TL arm. more...

Organism:: Homo sapiens

Type:: Expression profiling by high throughput sequencing

Platforms:: GPL11154 GPL16791
265 Samples

Download data: TSV, TXT, XLS

Series

Accession:: GSE116335

ID:: 200116335

PubMed Full text in PMC Similar studies SRA Run Selector

Select item 2000108868.

A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes

(Submitter supplied) Purpose: The biological subtypes of breast cancer designated as Luminal A, Luminal B, HER2+/ER-, and Basal-like are clinically important for prognosis and planning treatment strategies. Recognizing that there is a continuum in both the spectrum of breast cancer disease and the risk of survival, we sought to develop a clinical test for the biological subtypes using a supervised risk classier.Methods: Microarray and real-time quantitative RT-PCR (qRT-PCR) data from 189 samples, procured as fresh-frozen and formalin-fixed, paraffin-embedded tissues, were used to statistically select prototypical samples and genes for the biological subtypes of breast cancer. more...